Humana (NYSE:HUM) Given New $380.00 Price Target at Bank of America

Humana (NYSE:HUM) had its price target lifted by analysts at Bank of America from $340.00 to $380.00 in a research note issued on Wednesday,MarketScreener reports. Bank of America‘s target price would suggest a potential upside of 4.59% from the stock’s current price.

Other research analysts also recently issued research reports about the company. Morgan Stanley boosted their price target on Humana from $217.00 to $249.00 and gave the company an “underweight” rating in a research note on Thursday, June 4th. The Goldman Sachs Group increased their price target on shares of Humana from $158.00 to $195.00 and gave the stock a “sell” rating in a research report on Thursday, April 30th. Barclays lifted their price objective on shares of Humana from $180.00 to $344.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 26th. Seaport Research Partners downgraded Humana to a “neutral” rating in a report on Wednesday, May 20th. Finally, Wells Fargo & Company lowered Humana from a “cautious” rating to a “reduce” rating in a research note on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $293.09.

Humana Trading Up 0.7%

Shares of HUM stock opened at $363.31 on Wednesday. The stock has a market cap of $43.62 billion, a P/E ratio of 38.81, a price-to-earnings-growth ratio of 2.05 and a beta of 0.76. Humana has a 1 year low of $163.11 and a 1 year high of $380.86. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The stock has a 50 day simple moving average of $292.50 and a 200 day simple moving average of $243.15.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. The firm had revenue of $39.65 billion for the quarter, compared to analyst estimates of $39.37 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.The company’s revenue was up 23.5% on a year-over-year basis. During the same quarter last year, the company earned $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS. On average, research analysts predict that Humana will post 9.04 earnings per share for the current fiscal year.

Institutional Trading of Humana

Hedge funds have recently made changes to their positions in the company. Long Focus Capital Management LLC acquired a new position in shares of Humana during the third quarter valued at about $34,212,000. Aberdeen Group plc raised its holdings in shares of Humana by 18.1% in the 4th quarter. Aberdeen Group plc now owns 283,778 shares of the insurance provider’s stock worth $72,684,000 after acquiring an additional 43,442 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Humana by 4.1% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 250,330 shares of the insurance provider’s stock valued at $66,207,000 after acquiring an additional 9,960 shares in the last quarter. Ninety One UK Ltd boosted its stake in Humana by 57.2% during the 4th quarter. Ninety One UK Ltd now owns 112,501 shares of the insurance provider’s stock valued at $28,815,000 after purchasing an additional 40,958 shares during the last quarter. Finally, Sustainable Insight Capital Management LLC boosted its stake in Humana by 23.7% during the 4th quarter. Sustainable Insight Capital Management LLC now owns 24,757 shares of the insurance provider’s stock valued at $6,341,000 after purchasing an additional 4,740 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.